samedan logo
home > ebr

European Biopharmaceutical Review


European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America, and the rest of the world.

With editorial consisting of in-depth articles, case studies, meetings, and report reviews written by specialists with hands-on experience in the biopharma industry; traditional multi-national pharma companies; investment houses; and industry-associated governmental, economic, and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:


Helga Schweissguth


Vanessa Kintu



Connect with us on Twitter: follow @EBRmagazine

Click here to view the digital version of EBR




Featured in this issue
Cell and Gene Therapy
The Challenges of AAV-Based Gene Therapy

Dr Hüseyin Besir and Dr Dana Holzinger at PROGEN

A lack of suitable and widespread reference material in gene therapy is just one of the many obstacles facing laboratories around the world attempting to find treatments for genetic diseases
Making the Right Choices for Reliable HCP Monitoring by ELISA

Martin Föge and Stefan Sommerschuh at BioGenes

The clearance of biopharmaceutical drugs from host cell protein (HCP) impurities during manufacturing remains a constant challenge, necessitating the reliable monitoring of their removal from the final drug product. The ELISA is the broadly accepted gold standard for HCP monitoring. Important steps for customised HCP ELISA development will be discussed
  Cell and Gene Therapy
The Role of ddPCR in Developing Safe and Effective AAV-Based Gene Therapies

Mark White at Bio-Rad

There are a number of bioprocessing hurdles AAV developers must overcome to insure the generation of a safe and effective product. Luckily, there are also a number of technological solutions that can help face these challenges


Published quarterly in
January, April,
July, and October


Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

News and Press Releases

Bilim Pharmaceuticals, H&T Presspart and Hovione Technology unveil collaboration for new asthma product: Ventofor Combi Fix delivered by PowdAir Plus

1st September 2020 – Bilim Pharmaceuticals, a Turkish company manufacturing and marketing pharmaceutical drugs, H&T Presspart, a global provider of respiratory drug-delivery devices and components to the pharmaceutical sector, and Hovione Technology, a pharmaceutical specialist in the development of innovative pulmonary device technology, today unveiled a collaboration supporting Bilim Pharmaceutical’s launch into the Turkish market of Ventofor Combi Fix, a formulation of Budesonide Formoterol for Asthma and COPD management, delivered by the PowdAir Plus Dry Powder Inhaler (DPI).
More info >>

White Papers

Finding the Right End-to-End Safety Solution for Your Needs


With upcoming changes, including the implementation of the International Conference on Harmonisation (ICH) E2B(R3) Electronic Transmission of Individual Case Safety Report and Identification of Medicinal Products (IDMP) standards, the current state of safety reporting can be confusing. Your existing safety system may not be flexible enough to accommodate these changing regulations, which are still moving targets regarding the details needed for a comprehensive solution with the right level of processes, company-to-company integrations and finalized regional rules.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement